Top Banner
PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors Scott Kopetz 1 , Jayesh Desai 2 , Emily Chan 3 , J Randolph Hecht 4 , Peter J O’Dwyer 5 , Richard J Lee 6 , Keith B Nolop 7 , Suman Bhattacharya 8 , Leonard Saltz 9 1 The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2 Royal Melbourne Hospital, Parkville, Australia; 3 Vanderbilt-Ingram Cancer Center, Nashville, TN; 4 David Geffen School of Medicine at UCLA, Los Angeles, CA; 5 Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA; 6 Roche, Nutley, NJ; 7 Plexxikon, Berkeley, CA; 8 Genentech, Inc., South San Francisco, CA; 9 Memorial Sloan-Kettering Cancer Center, New York, NY
15

PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Feb 22, 2016

Download

Documents

cleave

PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors. Scott Kopetz 1 , Jayesh Desai 2 , Emily Chan 3 , J Randolph Hecht 4 , Peter J O’Dwyer 5 , Richard J Lee 6 , Keith B Nolop 7 , Suman Bhattacharya 8 , Leonard Saltz 9 - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Scott Kopetz1, Jayesh Desai2, Emily Chan3, J Randolph Hecht4 , Peter J O’Dwyer5, Richard J Lee6, Keith B Nolop7, Suman Bhattacharya8, Leonard Saltz9

1 The University of Texas M.D. Anderson Cancer Center, Houston, TX; 2 Royal Melbourne Hospital, Parkville, Australia;

3 Vanderbilt-Ingram Cancer Center, Nashville, TN; 4 David Geffen School of Medicine at UCLA, Los Angeles, CA;

5 Abramson Cancer Center at University of Pennsylvania, Philadelphia, PA; 6 Roche, Nutley, NJ;

7 Plexxikon, Berkeley, CA; 8 Genentech, Inc., South San Francisco, CA;

9 Memorial Sloan-Kettering Cancer Center, New York, NY

Page 2: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 3: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 4: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 5: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 6: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 7: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 8: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 9: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 10: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 11: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 12: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 13: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 14: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534

Page 15: PLX4032 in Metastatic Colorectal Cancer Patients with Mutant BRAF Tumors

Kopetz, Desai, et al ASCO 2010 Abs# 3534